Results 51 to 60 of about 34,967 (216)

A real‐world analysis of AI chatbot performance for medicines information enquiries

Journal of Pharmacy Practice and Research, EarlyView.
Abstract Background The provision of medicines information (MI) services requires interpretation and clinical judgement of complex scenarios by pharmacists. To date, few studies have assessed the performance of artificial intelligence (AI) chatbots to assist pharmacists providing MI advice.
Duncan Yorkston, Tracey Borrie, Paul Chin   +2 more
wiley   +1 more source

Evaluation of Rivaroxaban Exposure via Anti-Xa Levels During VTE Prophylaxis in Hospitalized Patients

Clinical and Applied Thrombosis/Hemostasis
Rivaroxaban was FDA-approved in 2019 for venous thromboembolism (VTE) prophylaxis in acutely ill hospitalized patients. Little to no published data is available to determine the level of correlation between rivaroxaban drug concentration and UFH/LMWH ...
Kaitlin Blotske PharmD, Toral Patel PharmD, BCPS, Toby Trujillo PharmD, FCCP, FAHA, BCPS, Matthew Marlar MLS (ASCP), Stuart Lind MD, Henry Kramer MD, Kathryn Hassell MD, Tyree H. Kiser PharmD, FCCM, FCCP, BCCCP, BCPS   +7 more
doaj   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation

TH Open, 2018
Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim, Calvin H. Yeh, Brian J. Dale, Beverly A. Leslie, Alan R. Stafford, James C. Fredenburgh, Jack Hirsh, Jeffrey I. Weitz   +7 more
doaj   +1 more source

Bioactive Natural Products in Cardiovascular Disease: Focus on Thrombotic Events

Phytotherapy Research, EarlyView.
An overview of the role of natural products (NP) in cardiovascular disease prevention, highlighting key mechanisms of action: including antiplatelet, antithrombotic, anti‐inflammatory, and antioxidant effects. Additionally, it illustrates the integration of diet–drug interactions, nutritional epigenetics, and the role of artificial intelligence in ...
Maria Nektaria Magkoulia, Despoina Pantazi   +1 more
wiley   +1 more source

Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran

BMC Health Services Research
Background Low-dose aspirin and rivaroxaban are the cornerstone treatment for cardiovascular prevention in patients with peripheral artery disease (PAD) and/or stable coronary artery disease (SCAD).
Zahra Goudarzi, Zhila Najafpour, Ahmad Gholami, Khosro Keshavarz, Mohammad Mahdi Mojahedian, Mohammad Mehdi Babayi   +5 more
doaj   +1 more source

Whole‐Body CT Utilisation in Adult Trauma: Guideline Compliance, Incidental Findings, and the Role of Anticoagulation in Low‐Energy Falls at a Regional New Zealand Centre

Journal of Medical Imaging and Radiation Oncology, EarlyView.
ABSTRACT Introduction Whole‐body CT (WBCT) is central to major trauma assessment, but indiscriminate use carries a substantial radiation burden. The Central Region Trauma Network's Early Radiological Imaging in Major Trauma Guideline (CPG154), adopted at this centre, specifies criteria for WBCT and excludes low‐energy falls from standing height.
Vamsi Thammandra, Jonny Russell
wiley   +1 more source

Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases [PDF]

, 2013
We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion who received rt-PA for thrombolysis while on oral anticoagulant treatment with dabigatran (150 mg b.i.d.).
Baas, Horst, Mario Abruscato, Susanne Hövelmann, Pfeilschifter, Waltraud, Abruscato, Mario Giovanni Rosario, Hövelmann, Susanne, Horst Baas, Waltraud Pfeilschifter   +7 more
core   +1 more source

Pulmonary Embolism—A Century of Progress

ANZ Journal of Surgery, EarlyView.
Reviews a century of progress in the diagnosis, prevention, and management of pulmonary embolism; from the first successful surgical embolectomy in 1924 to advanced imaging, pharmacological thromboprophylaxis, and treatment. In the 21st century, advances include catheter‐directed thrombolysis or mechanical thrombectomy under decision‐making guidance of
D. A. Watters
wiley   +1 more source

Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial

, 2020
Aims: To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban.
Barco, S., Bauersachs, R. M., Lankeit, M., Otero Candelera, Remedios, Schmidtmann, I., Bernardi, E., Ageno, W., Becattini, C.   +7 more
core   +1 more source